Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.59 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.59 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
| ▸ | PI4KA | P42356 | 2/20 | 0.47 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.47 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258583 | 1.00 | PDPK1 (0.59) | PDPK1GDAMAP3K5CYP1A2CYP3A4 | |
| SCHEMBL1330116 | 0.88 | PDPK1 (0.54) | PDPK1GDAMAP3K5CYP1A2CYP3A4 | |
| SCHEMBL4408536 | 0.83 | PDPK1 (0.56) | PDPK1GDAMAP3K5CYP1A2CYP3A4 | |
| SCHEMBL9351658 | 0.79 | CYP1A2 (0.51) | PDPK1GDAMAP3K5CYP1A2CYP3A4 | |
| SCHEMBL639898 | 0.79 | DPP4 (0.56) | PDPK1GDAMAP3K5CYP1A2CYP3A4 | |
| SCHEMBL31527929 | 0.79 | CYP1A2 (0.51) | PDPK1GDAMAP3K5CYP1A2CYP3A4 | |
| SCHEMBL30834788 | 0.77 | CYP1A2 (0.50) | PDPK1GDAMAP3K5CYP1A2CYP3A4 | |
| SCHEMBL5039982 | 0.77 | ADORA3 (0.56) | PDPK1GDACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5144928 | 0.77 | XDH (0.56) | PDPK1GDACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL31012324 | 0.76 | CYP2C19 (0.63) | PDPK1GDAMAP3K5CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705481-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4634380-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| WO-2024233308-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | claimed |
| WO-2024129779-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| WO-2024123812-A1 | FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES | SHATTUCK LABS, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| WO-2024097875-A1 | FUSION PROTEINS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS | SHATTUCK LABS, INC. (US) | 2024-05-10 | — | — | WO | claimed |
| WO-2026102302-A1 | POLYNUCLEOTIDES CONTAINING A MODIFIED 3'-REGION | MODERNATX, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4728063-A1 | METHODS OF SIMULTANEOUSLY IDENTIFYING OR QUANTIFYING CAPPING AND TAILING MODIFICATIONS OF MESSENGER RNA | Sanofi Pasteur Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4704884-A1 | ANTIGEN-SPECIFIC PHYSIOLOGIC DENDRITIC CELLS FOR VACCINATION | Yale University (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4704883-A1 | ANTIGEN-SPECIFIC PHYSIOLOGIC DENDRITIC CELLS FOR THERAPY | Yale University (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2025184082-A9 | NOVEL CAP ANALOGS AND METHODS OF USE THEREOF | TRILINK BIOTECHNOLOGIES, LLC (US) | 2026-02-26 | — | — | WO | disclosed |
| EP-4687990-A1 | METHOD OF SYNTHESIS OF TARGETED LIPID NANOPARTICLE AND USES THEREOF | OSE IMMUNOTHERAPEUTICS (FR) | 2026-02-11 | — | — | EP | disclosed |
| EP-4677078-A1 | MANUFACTURE OF MESSENGER RNA WITH KP34 POLYMERASE | Sanofi Pasteur Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-4097253-A1 | CLOSED LINEAR DNA WITH MODIFIED NUCLEOTIDES | Tyris Therapeutics, S.L. (ES) | 2022-12-07 | — | — | EP | disclosed |
| EP-4097252-A1 | PROCESS FOR THE PRODUCTION OF CLOSED LINEAR DNA | Tyris Therapeutics, S.L. (ES) | 2022-12-07 | — | — | EP | disclosed |
| EP-4090664-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | Bristol-Myers Squibb Company (US) | 2022-11-23 | — | — | EP | disclosed |
| WO-2022234417-A1 | IMMUNOGENIC COMPOSITION AGAINST INFLUENZA | PFIZER INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022232810-A1 | PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022226377-A1 | COMPOSITIONS AND METHODS FOR MODULATING SOS GENE EXPRESSIONS | MOLECULAR AXIOM, LLC (US) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022122689-A1 | RNA MANUFACTURING | BioNTech SE (DE) | 2022-06-16 | — | — | WO | disclosed |